Enlicitide decanoate
Highest phase reached
Phase 3
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Protein
- Drug name
- Enlicitide decanoate
- Molecular weight
- 1,722.12
- Structure (SMILES)
- CCCCCCCCCC(=O)[O-].COc1ccc(C[C@@H]2NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]3[C@@H]4CCN3C(=O)[C@@H]3Cc5cn(c6ccc(F)cc56)CCCCCCN(Cc5ccc(cc5)CCNC(=O)[C@]5(C)CCCN5C2=O)C(=O)CCC(=O)N[C@@H](C)C(=O)N[C@H](CNC(=O)CCCCC[N+](C)(C)C)C(=O)N[C@@H](Cc2cccc(c2)CNC(=O)CO4)C(=O)N3)cc1
- enlicitide decanoate
- Enlicitide decanoate
- Enlicitide Decanoate
- ENLICITIDE DECANOATE [USAN]
- Enlicitide decanoate [WHO-DD]
- enlicitide decanoate usan
- enlicitide decanoate who dd
- lipfendra
- LIPFENDRA
- mk 0616
- Mk-0616
- MK-0616
- CAS registry numbers
- 2861205-06-1
- ChEMBL ID
- CHEMBL6068420
- InChIKey
- ZMLCOVYFOZPADV-QQCDJELVSA-N
- PubChem compound IDs
- 172866837
- FDA ingredient codes (UNII)
- PSR59MCX5M
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -tide
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Atherosclerosis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003914
- Subject identifier
- D050197
- Condition
- Hyperlipoproteinemia Type II
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004911
- Subject identifier
- D006938
- Condition
- Hypercholesterolemia
- Highest recorded phase
- 3
- Condition identifier
- HP:0003124
- Subject identifier
- D006937
- Condition
- Lipid Metabolism Disorders
- Highest recorded phase
- 1
- Condition identifier
- Orphanet:309005
- Subject identifier
- D052439
- Condition identifier
- EFO_0003914
- Condition identifier
- HP_0003124
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005311
- Condition identifier
- MONDO_0005439
- Highest recorded phase
- 3
- NCT05070390
- NCT05261126
- NCT06450366
- NCT05934292
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 124
- Molecular formula
- C92H129FN14O17
- Monoisotopic mass
- 1720.96441686
- Natural product
- No
- 0006-5084
Related records
Trials (14)
- A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)
- A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
- A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
- A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
- A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)
- A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)
- A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)
- A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)
- A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)
- A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024)
- Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
- Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)
- Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
- The Effect of Food and Water Volume in Healthy Adult Participants Administered Enlicitide Decanoate (MK-0616) (MK-0616-022)
In development for (4)
- Atherosclerosis Phase 1
- Familial hypercholesterolemia Phase 2
- Inherited lipid metabolism disorder Phase 1
- Kidney disorder Phase 1